Schaeffer's Top Stock Picks for '25

Analysts, Shorts Divided on Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics Inc (STML) is a favorite among analysts, but short sellers aren't convinced

Dec 31, 2014 at 2:28 PM
facebook X logo linkedin


A number of biotech stocks are rallying this afternoon, including Stemline Therapeutics Inc (NASDAQ:STML). At last check, shares of the cancer treatment developer are up nearly 9% at $17.22 -- but remain 12.2% lower year-to-date. Meanwhile, a look around Wall Street reveals little in the way of a consensus opinion.

On the one hand, the brokerage bunch is extremely bullish toward STML, with 100% of covering analysts doling out a "strong buy" rating. Additionally, the equity's consensus 12-month price target of $54.60 more than triples the current stock price. Last week, Aegis Capital cut STML's target price by $7 to $68 -- but that still represents a premium of almost 50% to STML's record high of $47.25, touched last October.

On the flip side, short sellers have been betting on downside for STML. Roughly one-tenth of the security's float is sold short, which would take about nine days to buy back, at typical daily trading volumes. In fact, current short interest levels are just a chip-shot away from the all-time peak touched earlier this month.

Looking ahead, Stemline Therapeutics Inc (NASDAQ:STML) is scheduled to make an appearance at the J.P. Morgan Healthcare Conference on Jan. 15 in San Francisco. This event could provide a catalyst, either to the upside or downside. What's more, an ensuing shift in sentiment -- in the form of either bearish brokerage notes or short-covering activity -- could further intensify any such move.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?